Online inquiry

IVTScrip™ mRNA-Anti-CD3E, NI-0401(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12398MR)

This product GTTS-WQ12398MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD3E gene. The antibody can be applied in Crohn's disease (CD), Psoriasis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000733.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916
UniProt ID P07766
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E, NI-0401(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12398MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13484MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA PRTX-100
GTTS-WQ6372MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CSL654
GTTS-WQ10618MR IVTScrip™ mRNA-Anti-PDCD1, LY3300054(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY3300054
GTTS-WQ7060MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA Fab-12 variant Y0317
GTTS-WQ2523MR IVTScrip™ mRNA-Anti-CALCRL, AMG 334(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG 334
GTTS-WQ723MR IVTScrip™ mRNA-Anti-TNFSF13B, A-623(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA A-623
GTTS-WQ2435MR IVTScrip™ mRNA-Anti-TSLP, AMG 157(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 157
GTTS-WQ6152MR IVTScrip™ mRNA-Anti-CTLA4, CP-675(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CP-675
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW